HIV 1 News and Research

RSS

Calypte begins U.S. initiative

Calypte Biomedical Corporation has announced that it has leased an 11,000+ square foot site located in Portland, Oregon.

10 Jul 2007

Number of new HIV cases in Sweden increases 40%

The number of new HIV cases recorded during the first half of this year in Sweden has increased 40% compared with the same time period last year and is at a record high, Xinhuanet reports.

10 Jul 2007

Women's HIV/AIDS conference delegates develop action plan to foster women's, girls' leadership in fight against disease

Delegates on Saturday at the close of the first International Women's Summit on Women's Leadership and HIV and AIDS in Nairobi, Kenya, released a 10-point action plan that aims to foster leadership roles of women and girls in the fight against HIV/AIDS, the Nation/AllAfrica.com reports.

10 Jul 2007

El Salvador needs to take increased HIV/AIDS control efforts

Although health officials in El Salvador have launched an HIV testing campaign in the country, some advocates say that the country needs to take increased efforts to control the growing number of HIV cases in the country, Inter Press Service reports.

10 Jul 2007

Etravirine reduces HIV viral loads when taken with Prezista

The experimental antiretroviral drug etravirine, made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals, greatly reduces HIV viral loads in people with a history of drug resistance when taken in combination with Tibotec's antiretroviral Prezista, according to two studies published Saturday in the journal The Lancet.

10 Jul 2007

U.S. NIH funded trial of VivaGel in sexually active young women commences

Starpharma Holdings Limited today announced the commencement in the U.S. of a trial to assess the safety and acceptability of SPL7013 Gel (VivaGel) in sexually active young women.

9 Jul 2007

Ownership of genetic information

We all share our genetic make up with relatives, but should we also share ownership of the results of DNA analysis or should this knowledge be considered private?

9 Jul 2007

Olive-pomace oil slows down AIDS

Olive oil has become part of the fight against the Human Immunodeficiency Virus (HIV) - the cause of AIDS - thanks to the research carried out by the Bionat team, from the University of Granada, headed by Prof. Andres Garcia-Granados, senior lecturer in Organic Chemistry.

9 Jul 2007

Self-monitoring helps reduce high-risk behavior among HIV-positive people

There are many effective, albeit expensive, intervention programs aimed at encouraging HIV-positive people to practice less risky behavior.

9 Jul 2007

How the HIV virus mutates to escape the body's immune system

A pioneering collaborative study has discovered how the HIV virus evades the human body's immune system.

9 Jul 2007

HIV prevalence in India is approximately 0.36%

The new 2006 estimates released by the National AIDS Control Organization (NACO), supported by UNAIDS and WHO, indicate that national adult HIV prevalence in India is approximately 0.36%, which corresponds to an estimated 2 million to 3.1 million people living with HIV in the country.

9 Jul 2007

Cancer risk in HIV, transplant patients

HIV/AIDS and kidney transplant patients are at much greater risk of contracting 20 different types of cancer than the general population, according to a land mark paper in The Lancet.

8 Jul 2007

Pre-exposure prophylaxis for HIV infection

Clinical trials of pre-exposure prophylaxis - that is giving anti-retroviral drugs to non-HIV-infected individuals to prevent them becoming infected - are exploring whether the approach could lead to a large decrease in transmission of the virus with few or no side effects.

8 Jul 2007

Darunavir-ritonavir shows benefits for patients with HIV

Darunavir-ritonavir should be considered as a treatment option across the range of treatment-experienced patients with HIV infection, conclude Jose Madruga (Centro de Referencia e Treinamento DST/AIDS, Sao Paulao, Brazil) and colleagues in an Article in this week's issue of The Lancet.

8 Jul 2007

Etravirine effective for HIV supression

Treatment with TMC125 (etravirine) leads to better virological suppression than placebo as part of antiretroviral therapy in patients with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), conclude two randomised trials in this week's issue of The Lancet.

8 Jul 2007